J. May

University of Waterloo — Canada

Economics, Econometrics and Finance · Social Sciences

6h-index328citations51works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Economic and Financial Impacts of Cancer(27), Renal cell carcinoma treatment(24), Health Systems, Economic Evaluations, Quality of Life(23), Cancer Immunotherapy and Biomarkers(10), Bladder and Urothelial Cancer Treatments(3)

Publications51 total

EE132 Creation of a Novel Canadian Policy Model for Bladder Cancer
Value in Health·2025
MP37-01 A COST-UTILITY ANALYSIS OF ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB VERSUS NIVOLUMAB PLUS GEMCITABINE-CISPLATIN IN ADVANCED UROTHELIAL CARCINOMA
The Journal of Urology·2025
P641 – A cost-utility analysis of enfortumab vedotin and pembrolizumab versus nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma
European Urology·2025
MSR12 Analysis of Long-Term Survivorship (LTS) Rates for Stage 2B/2C Melanoma Using Published Real-World Data (RWD) and Data From Randomized Controlled Trials (RCTS)
Value in Health·2023
103P Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab
Immuno-Oncology Technology·2023Open Access
CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)
Value in Health·2023· 1 cited
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective
Journal of Medical Economics·2023· 5 citedOpen Access
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma
Journal of Comparative Effectiveness Research·2023· 2 citedOpen Access
Thoroughbred Racehorses in Hong Kong Require Vitamin D Supplementation to Mitigate the Risk of Low Vitamin D Status
Animals·2023· 2 citedOpen Access
EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia
Value in Health·2023Open Access
MSR54 Exploring Hidden Survival Heterogeneity Among First-Line (1L) Intermediate/Poor (I/P)-Risk Advanced Renal Cell Carcinoma (ARCC) Patients Treated with Nivolumab Plus Ipilimumab (NIVO+IPI) Via Parametric Mixture Models (PMM)
Value in Health·2023Open Access
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
PharmacoEconomics - Open·2023· 8 citedOpen Access
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
European Urology Oncology·2023· 9 citedOpen Access
Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.
Journal of Clinical Oncology·2023
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
PharmacoEconomics - Open·2023· 3 citedOpen Access
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma
Value in Health·2022· 7 cited
1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
Annals of Oncology·2022· 2 cited
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
Journal of Clinical Oncology·2022· 1 cited
Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system
Jornal Brasileiro de Economia da Saúde·2021· 3 citedOpen Access
668P Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
Annals of Oncology·2021· 1 cited
page 1 of 3Next →

Frequent Co-authors

Bill Malcolm(25), Flavia Ejzykowicz(20), Murat Kurt(19), Kyna Gooden(9), S. Klijn(9), Matthew D. Dyer(8), Danielle S. Chun(8), Sonja Kroep(7), S. Branchoux(6), Saby George(6), Toni K. Choueiri(5), Esra Şükran Çakar(5), Nikoletta Szabó(5), M. Grevinga(5), Ella X. Du(4), Keith A. Betts(4), David Cella(4), John Borrill(4), Robert J. Motzer(4), Su Ann Ho(4)